Theratechnologies Inc. (NASDAQ:THTX) Sees Significant Increase in Short Interest

Theratechnologies Inc. (NASDAQ:THTX) was the target of a large increase in short interest during the month of February. As of February 15th, there was short interest totalling 31,900 shares, an increase of 212.7% from the January 31st total of 10,200 shares. Approximately 0.2% of the shares of the company are sold short. Based on an average daily trading volume, of 123,000 shares, the short-interest ratio is presently 0.3 days.

Institutional Investors Weigh In On Theratechnologies

A number of hedge funds have recently modified their holdings of the business. Bank of America Corp DE boosted its holdings in Theratechnologies by 1,416.7% in the 4th quarter. Bank of America Corp DE now owns 16,487 shares of the company’s stock worth $30,000 after buying an additional 15,400 shares during the period. BNP Paribas Financial Markets bought a new position in Theratechnologies in the 4th quarter worth $36,000. Raymond James Financial Inc. bought a new position in Theratechnologies in the 4th quarter worth $27,000. JPMorgan Chase & Co. purchased a new position in shares of Theratechnologies during the fourth quarter valued at about $33,000. Finally, Hillsdale Investment Management Inc. purchased a new position in shares of Theratechnologies during the fourth quarter valued at about $108,000.

Theratechnologies Stock Performance

Shares of THTX stock traded up $0.03 during mid-day trading on Friday, reaching $1.65. 71,740 shares of the company’s stock traded hands, compared to its average volume of 117,445. Theratechnologies has a 12 month low of $1.08 and a 12 month high of $2.18. The firm has a 50 day moving average price of $1.74 and a two-hundred day moving average price of $1.45. The firm has a market capitalization of $75.87 million, a PE ratio of -16.50 and a beta of 1.26.

Analyst Upgrades and Downgrades

Separately, Research Capitl upgraded shares of Theratechnologies to a “strong-buy” rating in a research note on Friday, February 14th.

About Theratechnologies

Theratechnologies Inc, a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen.